Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study-Reference-Cited by-同舟云学术

Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

Published:2013-08 Issue:8 Volume:37 Page:911-916
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mesa Ruben A.,Shields Alan,Hare Thomas,Erickson-Viitanen Susan,Sun William,Sarlis Nicholas J.,Sandor Victor,Levy Richard S.,Verstovsek Srdan

Funder

Intel Corporation

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference34 articles.

1. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?;Hasselbalch;Leuk Res,2009

2. Myelofibrosis with myeloid metaplasia;Tefferi;N Engl J Med,2000

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients;Mesa;Cancer,2007

4. Ruxolitinib for the treatment of myelofibrosis: its clinical potential;Ostojic;Ther Clin Risk Manag,2012

5. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med,2005

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Rare Presentation of Extramedullary Hematopoiesis as an Adrenal Mass: A Case Report;Cureus;2024-02-21

2. COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm;Frontiers in Oncology;2021-01-08

3. The Rationale for Immunotherapy in Myeloproliferative Neoplasms;Current Hematologic Malignancy Reports;2019-06-21

4. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings;Health and Quality of Life Outcomes;2019-04-11

5. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain;Journal of Health Economics and Outcomes Research;2017-11-29